New hope for migraine sufferers: drug combo tested after CGRP failure
NCT ID NCT05550207
First seen Jan 04, 2026 · Last updated May 23, 2026 · Updated 29 times
Summary
This study tested a new drug called AXS-07 (a mix of meloxicam and rizatriptan) for treating migraine attacks in adults who had already tried an oral CGRP inhibitor without success. About 100 people took part in this open-label Phase 3 trial. The goal was to see if the drug could relieve headache pain and the most bothersome symptom without needing rescue medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Clinical Research Site
Colton, California, 92324, United States
-
Clinical Research Site
Fullerton, California, 92835, United States
-
Clinical Research Site
La Jolla, California, 92037, United States
-
Clinical Research Site
Los Angeles, California, 90067, United States
-
Clinical Research Site
Sherman Oaks, California, 91403, United States
-
Clinical Research Site
Stamford, Connecticut, 06905, United States
-
Clinical Research Site
DeLand, Florida, 32720, United States
-
Clinical Research Site
Hallandale, Florida, 33009, United States
-
Clinical Research Site
Hollywood, Florida, 33024, United States
-
Clinical Research Site
Miami, Florida, 33126, United States
-
Clinical Research Site
Ormond Beach, Florida, 31274, United States
-
Clinical Research Site
Oviedo, Florida, 32765, United States
-
Clinical Research Site
Pensacola, Florida, 32504, United States
-
Clinical Research Site
Winter Park, Florida, 32789, United States
-
Clinical Research Site
Stockbridge, Georgia, 30281, United States
-
Clinical Research Site
Avon, Indiana, 46123, United States
-
Clinical Research Site
Boston, Massachusetts, 02131, United States
-
Clinical Research Site
North Dartmouth, Massachusetts, 02747, United States
-
Clinical Research Site
Las Vegas, Nevada, 89102, United States
-
Clinical Research Site
Albuquerque, New Mexico, 87102, United States
-
Clinical Research Site
The Bronx, New York, 10466, United States
-
Clinical Research Site
Williamsville, New York, 14221, United States
-
Clinical Research Site
Philadelphia, Pennsylvania, 19114, United States
-
Clinical Research Site
Charleston, South Carolina, 29406, United States
-
Clinical Research Site
Knoxville, Tennessee, 37909, United States
-
Clinical Research Site
Nashville, Tennessee, 37203, United States
-
Clinical Research Site
Cypress, Texas, 77429, United States
-
Clinical Research Site
Sugar Land, Texas, 77478, United States
-
Clinical Research Site
Salt Lake City, Utah, 84107, United States
-
Clinical Research Site
Charlottesville, Virginia, 22911, United States
-
Clinical Research Site
McLean, Virginia, 22101, United States
Conditions
Explore the condition pages connected to this study.